Citius Pharmaceuticals (47N0) Stock Statistics & Valuation Metrics
Total Valuation
Citius Pharmaceuticals has a market cap or net worth of EUR 12.84M. The enterprise value is EUR 15.28M.
- Market Cap
- EUR 12.84M
- Enterprise Value
- EUR 15.28M
Share Statistics
Citius Pharmaceuticals has 27,452,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 27,452,570
- Owned by Insiders
- ―
- Owned by Institutions
- 5.17%
Financial Efficiency
Citius Pharmaceuticals’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -44.23%.
- Return on Equity (ROE)
- -0.55
- Return on Assets (ROA)
- -0.29
- Return on Invested Capital (ROIC)
- -44.23%
- Return on Capital Employed (ROCE)
- -0.45
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.63M
- Employee Count
- 23
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.01
Valuation Ratios
The current PE Ratio of Citius Pharmaceuticals is -0.27. Citius Pharmaceuticals’s PEG ratio is -0.00.
- PE Ratio
- -0.27
- PS Ratio
- 2.17
- PB Ratio
- 0.22
- Price to FCF
- -0.44
- Price to Operating Cash Flow
- -0.42
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Citius Pharmaceuticals had revenue of 0 and earned -37.43M in profits. Earnings per share was -3.38.
- Revenue
- 0
- Gross Profit
- -214.25K
- Operating Income
- -38.53M
- Pretax Income
- -38.68M
- Net Income
- -37.43M
- EBITDA
- -38.20M
- Earnings Per Share (EPS)
- -3.38
Cash Flow
In the last 12 months, operating cash flow was -34.87M and capital expenditures 4, giving a free cash flow of -34.87M billion.
- Operating Cash Flow
- -34.87M
- Free Cash Flow
- -34.87M
- Free Cash Flow per Share
- -1.33
Dividends & Yields
Citius Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -225.47%
- Earnings Yield
- -313.91%
Stock Price Statistics
- Beta
- -1.29
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 3.29
- 200-Day Moving Average
- 3.29
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Citius Pharmaceuticals upcoming earnings date is Dec 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Dec 17, 2026
- Ex-Dividend Date
- ―
Financial Position
Citius Pharmaceuticals as a current ratio of 0.62, with Debt / Equity ratio of 2.68%
- Current Ratio
- 0.62
- Quick Ratio
- 0.13
- Debt to Market Cap
- 0.07
- Net Debt to EBITDA
- 0.06
- Interest Coverage Ratio
- -143.87
Taxes
In the past 12 months, Citius Pharmaceuticals has paid 1.06M in taxes.
- Income Tax
- 1.06M
- Effective Tax Rate
- -0.03
Enterprise Valuation
Citius Pharmaceuticals EV to EBITDA ratio is -0.10, with an EV/FCF ratio of -0.16.
- EV to Sales
- 0.79
- EV to EBITDA
- -0.10
- EV to Free Cash Flow
- -0.16
- EV to Operating Cash Flow
- -0.16
Balance Sheet
Citius Pharmaceuticals has EUR 17.01M in cash and marketable securities with EUR 7.18M in debt, giving a net cash position of EUR 9.83M billion.
- Cash & Marketable Securities
- EUR 17.01M
- Total Debt
- EUR 7.18M
- Net Cash
- EUR 9.83M
- Net Cash Per Share
- EUR 0.36
- Tangible Book Value Per Share
- -EUR 0.85
Margins
Gross margin is 19.97%, with operating margin of -863.92%, and net profit margin of -651.27%.
- Gross Margin
- 19.97%
- Operating Margin
- -863.92%
- Pretax Margin
- -815.97%
- Net Profit Margin
- -651.27%
- EBITDA Margin
- -804.88%
- EBIT Margin
- -863.17%
Analyst Forecast
The average price target for Citius Pharmaceuticals is EUR 3.59, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 3.59
- Price Target Upside
- 9.03% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
